We are live on ! Find out more

ImmuCell

ICCC

Market cap $90.1M

9.92 USD

-0.05

0.5%

At close Updated Sep 25, 11:07 AM EDT

1 day

-0.5%

5 days

1.22%

1 month

0.81%

3 months

0.3%

6 months

54.04%

Year to date

67.57%

1 year

63.97%

5 years

3.01%

10 years

20.83%

About: ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.

Employees: 73

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 44.4%

Neutral 55.6%

Negative 0%

SRK Capital 2026 Semi-Annual Portfolio Update

SRK Fund I, LP increased 26.80% during the first half of the year. In contrast, the S&P 500 and the Russell 2000 returned 10.18% and 22.57%, respectively. ImmuCell delivered a strong first quarter in 2026, underscoring the earnings power and cash-flow potential of its core First Defense franchise after the company's strategic exit from Re-Tain. Since divesting its capital-intensive ammunition manufacturing business in April 2025, Outdoor Holding Company has operated as a pure-play, asset-light marketplace through GunBroker.com.

SRK Capital 2026 Semi-Annual Portfolio Update

Zacks Investment Research

ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2

ICCC's Q2 sales rise 11.5% y/y, but margins contract. A $2-million legal settlement boosts profit as the company plans a capacity expansion.

ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2

ImmuCell Corporation (ICCC) Q2 2026 Earnings Call Transcript

ImmuCell Corporation (ICCC) Q2 2026 Earnings Call Transcript

ImmuCell Corporation (ICCC) Q2 2026 Earnings Call Transcript

ImmuCell Q2 Earnings Call Highlights

ImmuCell NASDAQ: ICCC reported higher second-quarter sales and earnings as domestic demand for its calf scours prevention products increased, while the company outlined plans to invest about $8 million to more than triple manufacturing capacity by the end of 2027.

ImmuCell Q2 Earnings Call Highlights

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026

PORTLAND, Maine, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced its unaudited financial results for the quarter ended June 30, 2026.

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026

PORTLAND, Maine, Aug. 06, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, expects to report unaudited financial results for the quarter ended June 30, 2026 after the market closes on Thursday, August 13, 2026. The Company is planning to host a conference call and webcast on August 14, 2026, at 9:00 AM ET to review the unaudited financial results.

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026

ImmuCell: First Defense With Better Execution

ImmuCell's main value driver is First Defense. In my view, this is their core franchise and has real commercial momentum across year-round dairy customers. They've also shown improving manufacturing yields and redirected Re-Tain assets towards First Defense's production capacity. My main concern with ICCC is that it's heavily reliant on two main distributors, as well as concentrated on First Defense as its main product.

ImmuCell: First Defense With Better Execution

Zacks Investment Research

ImmuCell Posts Strong Preliminary Q2 Sales on U.S. Demand

ICCC reports an 11.5% rise in preliminary Q2 sales, driven by robust U.S. demand and improved product availability, extending the momentum from its strong Q1 performance.

ImmuCell Posts Strong Preliminary Q2 Sales on U.S. Demand

ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results

PORTLAND, Maine, July 09, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced preliminary, unaudited sales results for the second quarter of 2026. “Total sales for the three months ended June 30, 2026 were $7.2 million, an 11.5% increase compared to the three months ended June 30, 2025, driven by a 27.7% increase in domestic sales compared to 2025,” said Timothy Fiori, Chief Financial Officer of ImmuCell.

ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results

Zacks Investment Research

ICCC's Valuation Remains Premium: Is it Worth Overpaying for?

ImmuCell's premium valuation is backed by rising output, First Defense share gains and a sizable untapped calf-health market opportunity.

ICCC's Valuation Remains Premium: Is it Worth Overpaying for?

See News Rankings

Price charts implemented using Lightweight Charts™